{"a":[{"_":"AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies","$":{"href":"/biotech/abbvie-backed-adarx-plans-ipo-fund-array-clinical-stage-sirna-therapies","hreflang":"en"}}]}

IPO/OfferingPositive

AI Analysis

ADARx, an AbbVie-backed biotech, plans to pursue an IPO to fund clinical trials of its portfolio of next-generation siRNA therapies.

Importance:6/10

Sentiment:

0.60

IPOsiRNAAbbVie backedclinical stage

Related Companies

Read the original article

Published by FierceBiotech on September 6, 2026 2:27 PM